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ABSTRACT
Atopic dermatitis (AD), also known as atopic eczema, is a chronic inflammatory skin condition associated
with a significant health-related and socioeconomic burden, and is characterized by intense itch, disrup-
tion of the skin barrier, and upregulation of type 2-mediated immune responses. The United Kingdom
(UK) has a high prevalence of AD, affecting 11–20% of children and 5–10% of adults. Approximately 2%
of all cases of childhood AD in the UK are severe. Despite this, most AD treatments are performed at
home, with little contact with healthcare providers or services. Here, we discuss the course of AD, treat-
ment practices, and unmet need in the UK. Although the underlying etiology of the disease is still emerg-
ing, AD is currently attributed to skin barrier dysfunction and altered inflammatory responses.
Management of AD focuses on avoiding triggers, improving skin hydration, managing exacerbating fac-
tors, and reducing inflammation through topical and systemic immunosuppressants. However, there is a
significant unmet need to improve the overall management of AD and help patients gain control of their
disease through safe and effective treatments. Approaches that target individual inflammatory pathways
(e.g. dupilumab, anti-interleukin (IL)-4 receptor a) are emerging and likely to provide further therapeutic
opportunities for patient benefit.
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Introduction
Atopic dermatitis (AD), also known as atopic eczema, is a chronic
inflammatory skin condition associated with epithelial, immune,
and environmental factors. It is characterized by intense itch, dis-
ruption of the skin barrier, and upregulation of type 2-mediated
immune responses in the skin (1–4).
As a disease, AD is characterized by early age of onset, with
approximately 60% of AD cases in the UK diagnosed in the first
year of life (5). Prevalence of AD decreases with age, with 30% of
4-year-olds, 11–20% of school-aged children, and 5–10% of adults
diagnosed with AD (6,7). Data from the International Study of
Asthma and Allergies in Childhood (ISAAC) and other studies
(8–10) showed that among children within a general practitioner
(GP) setting or within the general population, the annual AD
prevalence varies between age groups, and highlighted differen-
ces between self-reported prevalence of AD in the open popula-
tion compared with physician-diagnosed disease in general
practice (10).
Severity of AD can be assessed objectively in a standardized
manner using the SCORing AD (SCORAD) index. Higher numbers
indicate greater severity, and the scale ranges from 0 to 103 (11).
Approximately 18% of all cases of childhood AD in the UK are
moderate (as defined by Ben-Gashir et al., SCORAD ¼ 16–40) and
2% severe (SCORAD 40) (4). The odds of having severe AD are
twice as great for children with AD onset during the first year of
life (4). Moderate-to-severe AD can not only impact a child’s phys-
ical development but can also have psychological sequelae,
placing a substantial burden on parents and carers (12,13).
Fortunately, diagnosis of AD is typically accurate in secondary
care – a review of dermatology cases over a 25-year period in
Scotland identified AD with 97% accuracy (14). However, given
that most treatments are performed at home with little GP or
hospital services involvement, there remain significant challenges
with associated health-related and socioeconomic burdens (12,13).
The individual financial cost for AD
A recent study in the United States of America (USA) investigated
the costs, stratified by severity, for adults with moderate-to-severe
AD inadequately controlled with topical therapy, or for whom
topical therapies were medically inadvisable (15). The average life-
time cost for usual care was 271,356 USD for patients with moder-
ate AD and 271,579 USD for patients with severe AD (15).
Because of the differences between healthcare systems in the UK
and USA, however, it is difficult to correlate these lifetime costs
with the financial burden in the UK.
A study comprised of adults with AD from nine different
European countries including the UK found that out-of-pocket
costs accounted for about 900 EUR (800 GBP) per year, includ-
ing moisturizers and emollients, medications, travel expenses, and
other costs. Additionally, many patients had extra costs related to
everyday expenses, such as the purchase of extra or special clean-
ing products or washing powder (laundry detergent), bedding, or
clothing that otherwise would not be purchased (16).
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On top of direct costs, indirect costs associated with AD
include disruption of employment (time off work, reduction in
employment, and loss of productivity). In the European study,
26% of patients missed 6–10 days at work within the last year
due to their AD, and over half missed 1–5 days. Patients with
moderate-to-severe AD were more likely to miss work (16). In
addition to patients themselves, indirect costs affect carers as
well. For example, mothers of children with AD were found to be
less likely to take up outside employment or to pursue leisure
activities compared with mothers of children without
AD (13,17,18).
It is unclear how the financial burden of AD impacts treatment
compliance in patients (19–22). The large-scale International Study
of Life with Atopic Eczema (ISOLATE) investigated the effect of
AD on patients’ lives and society; it examined how patients and
their carers coped with AD and how well they believed their dis-
ease was being controlled. Most of the patients in the study were
prescribed reactive topical corticosteroid (TCS)-based AD therapies
(20). Although effective, concerns over TCSs led to compliance
issues and treatment delays or restrictions, resulting in 39% of
participants using TCSs less frequently and for shorter periods
than was recommended, and 66% using TCSs only as a last resort.
The results of ISOLATE highlight AD as an undertreated disease,
which, despite the availability of effective therapies, has consider-
able, yet often avoidable, adverse effects on patients, their carers,
and society – including socioeconomic costs (e.g. unemployment,
lost productivity, and an impact on schoolwork, learning, and aca-
demic performance among younger patients) (20).
An audit commissioned by the British Association of
Dermatologists provided data on the national service outcomes of
235 patients with AD in secondary care in the UK (23). The audit
gathered information from patients using pre- and post-consult-
ation questionnaires in 29 hospital dermatology departments ran-
domly selected from 187 centers. The outcomes measured were
quality of life (QoL), sleep improvement, improvement in the
worst aspect of AD, and the ability to return to work or school
(23), and were based on audit standards established by the British
Association of Dermatologists and the Research Unit of the Royal
College of Physicians (24).
An improvement in QoL (>25%) was reported in 49% of adults
and 44% of children, and improved sleep was reported in 44% of
adults and 47% of children; however, these results fell short of
the working standards of 60% for QoL and 70% for improved
sleep. Further, an improvement in the worst aspect of AD was
reported in 61% of adults and 59% of children, but that too fell
short of the working standard of 80%. Although 87.5% of children
returned to school within 6 weeks and met the working standard
of 80%, only 70% of adults returned to work, again falling short
of the working standard (23). It should be taken into account that
only a small percentage of AD patients are referred to dermatolo-
gists for care in the UK (4% of children aged 1–5) (19) therefore
poor outcomes may reflect selection bias for patients with severe
and recalcitrant disease. Nevertheless, these studies demonstrate
a significant need to improve the management of AD and help
patients gain control of their disease.
Pathogenesis and course of AD
Although the underlying etiology of AD is not fully known, it is
believed to be attributable to complex, yet interrelated, biologic
pathways, including dysfunction of the skin barrier and altered
innate or adaptive immune responses (25). There is increasing
evidence that disruption of the skin barrier function and atopy
affect one another reciprocally, ‘driving’ the progress of
AD (26–28).
The stratum corneum (SC) is composed of corneocytes, termin-
ally differentiated enucleated keratinocytes that are densely
packed with lipids and proteins (29). Filaggrin contributes to SC
function through many roles, including keratin cross-linking,
hydration, and pH modulation (30–34). Filaggrin is naturally bro-
ken down in the SC into several compounds that are the constitu-
ents of natural moisturizing factor (NMF) (31,33,35). NMF is
essential for optimal SC hydration, desquamation, plasticity, and
acidity, and it provides the optimal environment for commensal
microorganisms colonizing the skin (32,33,35,36). Disruption of
the healthy epidermal microbiome can be associated with skin
disorders or infections by potentially pathogenic bacteria such as
Staphylococcus aureus (37–39).
Many genetic factors influence the integrity of the skin in AD,
including mutations in genes encoding structural proteins, such
as filaggrin (25,40). Loss-of-function mutations in the gene encod-
ing filaggrin (FLG) have been associated with early-onset, severe,
and long-lasting AD, and are considered to be the most signifi-
cant genetic risk factor for developing the disease (25,26).
Mutations in proteases and protease inhibitors also play an
important role in AD, leading to altered desquamation and
defects in the skin barrier (40–42). These and other immunological
genetic factors (43–45) are thought to provide the underlying sus-
ceptibility that may predispose individuals to develop
AD (25,41,42,46–48).
Environmental trigger factors are believed to play an important
role in the progression of disease and development of AD (49).
Data obtained (at age 7, 11, and 16 years) from 828 children born
in 1958 showed a marked and statistically significant geographical
variation in AD prevalence. The highest risk was associated with
London and the South-East, North Midlands, Eastern, and
Southern regions of the UK (49). In other studies, urban areas
have been shown to have a higher risk of severe disease than
rural areas (4,50). These regions may be associated with environ-
mental factors such as temperature and humidity, allergen expos-
ure, microbial exposure, pollution, and lifestyle factors (51,52). Itch
is a key symptom of AD and promotes physical disruption of the
skin barrier (53), which can promote the penetration of allergens
such as the house dust mite Dermatophagoides protease (Der p1).
Such proteases have been linked directly to the degradation of
the skin barrier (54–56). Other environmental factors known to
impact AD include water hardness and contaminants in water
(57), soaps and detergents (58,59), and prolonged use of
TCSs (60,61).
AD is a product of interplay between such environmental fac-
tors and genetic susceptibility. The loss-of-function FLG mutation
results in decreased levels of filaggrin and, consequently, reduced
NMF. Low levels of NMF increase transepidermal water loss and
elevate SC pH levels (33,35). This altered skin environment can
lead to S. aureus infection (62,63), which in turn leads to skin
inflammation and systemic immunoglobulin (Ig) E sensitization
(64–66). S. aureus can damage the skin barrier directly and secrete
exotoxins that can activate an immune response to allergens pen-
etrating the skin barrier (64,65,67–69). For example, one S. aureus
exotoxin functions as an adjuvant to promote the inflammatory
response to Der p1 (70).
The penetration of allergens through the defective skin barrier
results in interaction with local immune cells and in the release of
AD-related pro-inflammatory cytokines (27,54,71–78).
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During the initial or acute phase of AD, a type 2 (including
innate lymphoid cells [ILCs] and T helper type 2 cells [Th2])
immune response characterized by interleukin (IL)-4, IL-13, and IL-
5 predominates (Figure 1) (79–81). This may, in part, be related to
the release from keratinocytes of type 2-driving alarmins (IL-25, IL-
33, and thymic stromal lymphopoietin [TSLP]). In the chronic
phase, a mixed response involving Th1, Th17, and Th22 immune
cells can be observed (74–78,82,83).
Lesional skin biopsies from patients with acute and chronic AD
are enriched for the type 2 cytokines IL-4, IL-5, IL-13, IL-31, and IL-
33 (75,79–81). The IL-4 and IL-13 cytokines are critical for further
type 2 polarization and the development of AD (80,84–87). IL-5 is
produced by Th2 cells and other cells and promotes eosinophilic
inflammation in atopic diseases (88). IL-31, primarily produced by
Th2 cells and mast cells in response to antimicrobial peptides, is
significantly increased in AD, and it has been implicated in the
regulation of itch (53,89). IL-33 activates Th2 cells, ILCs, mast cells,
neutrophils, and eosinophils in response to allergen or S. aureus
exotoxin exposure and other triggers (77,78,90). Recently, it was
shown that house dust mite-derived phospholipases act on the
skin to produce antigenic neolipids that are presented by CD1a
for recognition by T cells. The production of type 2 cytokines by
ILCs, peptide-specific major histocompatibility complex-restricted
T cells, and lipid-specific CD1a-reactive T cells supports the gener-
ation of allergen-specific IgE (28,91). Type 2 cytokines have also
been shown to contribute to the skin barrier dysfunction by mod-
ulating the expression of structural proteins and antimicrobial
peptides – key to maintaining the skin integrity – and thereby
facilitating allergen penetration through the skin (Figure 1)
(27,92). Both increased allergen-specific IgE presentation and aller-
gen penetration through the skin barrier potentiate the inflamma-
tory response.
The generation of IgE antibodies and skin-derived TSLP is asso-
ciated with the development of other atopic disorders, including
asthma, allergic rhinitis, and/or food allergies (93–97).
Additionally, AD has recently been shown to be associated with
non-atopic disorders, including cardiovascular disease (98,99) and
some forms of cancer (100). The relation of localized skin disor-
ders with systemic disease represents one of the largest chal-
lenges for treating AD and associated morbidity (101). Early and
effective management of AD may therefore have effects beyond
the skin.
AD treatment in the UK
The aim of the guidance and information available on skin condi-
tions provided by the UK’s National Health Service (NHS) is to
facilitate a whole system-integrated approach for people with AD
that ensures timely access, high-quality care (close to home,
where applicable), and value for money (102). In England and
Wales, the NHS directive uses the standards set for patient care
by the National Institute for Health and Care Excellence (NICE).
The NICE guidelines cover the diagnosis and management of AD
in children and adults to improve care and QoL, and to decrease
the physical severity of their disease (103,104).
The management of AD in the UK occurs predominantly in the
primary care setting, and current treatment options include
approaches intended to protect the skin barrier (e.g. emollients
[leave-on and wash], medicated bandages) or reduce inflamma-
tion (TCSs, topical calcineurin inhibitors [TCIs], broad immunosup-
pressants, biologics). Also significant in the management of AD is
the identification, avoidance, and treatment of exacerbating envir-
onmental factors. As discussed above, disruptions in the skin bar-
rier result in greater exposure to allergens, and avoiding such
allergens can play a role in the management of AD. For children
Figure 1. Skin barrier dysfunction and immune response in atopic dermatitis (AD). DC: dendritic cell; IFN-c: interferon gamma; ILC: innate lymphoid cell; IL: interleukin;
IL-17 A/F: IL-17 A/F homodimer or heterodimer; LC: Langerhans cell; Th1: T helper type 1 cell; Th17: T helper type 17 cell; Th2: T helper type 2 cell; Th22: T helper
type 22 cell; TSLP: thymic stromal lymphopoietin.
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under the age of 12 years, a stepwise approach should be taken
to manage the disease, with the potency of the medications
adapted to the severity of the disease and the anatomical site of
application (Table 1) (103).
According to the NICE guidelines, the treatment options for
children with AD should be tailored to meet the needs of the
patient. Emollients such as creams, ointments, sprays, lotions,
gels, and bath additives are considered first-line therapies and are
selected by the patient (103,105). Emollients are products that
contain various moisturizing components that improve symptoms,
including humectants (hygroscopic substances that attract water)
and non-physiologic lipids. The lipids provide an artificial protect-
ive layer over the surface of the skin that aids water retention
and transiently improves skin barrier function. Emollients can help
soften skin texture and help relieve the pruritus (itch) caused by
excessive dryness (106), and some may even reduce the need for
TCSs (107). Simple emollients are tolerated in children as young
as 6 months (103,108).
The accepted best practice for emollient therapy recommends
consistent and liberal use of emollients and skin protectants.
Recent evidence suggests that not all emollients for the protec-
tion and maintenance of the skin barrier are the same, with some
displaying additional physiological effects on the skin and others
having adverse effects (109–112). For example, some emollients
contain surfactants and emulsifying agents (such as sodium lauryl
sulfate) that not only disrupt the epidermal barrier function
(113,114) but can also irritate the skin and induce an immune
response (58,115). In contrast, other emollients appear to delay
the onset of flares and may even help prevent the primary emer-
gence of AD (116,117). As such, many uncertainties still remain
regarding the use of emollients, including which emollient to use
and how much (118).
Bathing, by soaking in lukewarm water with emollients (and
possibly short-term/intermittent antimicrobials), offers an oppor-
tunity to improve skin hydration, provides symptomatic relief of
AD symptoms, and has an antipruritic effect (103,106). However,
bathing can also cause dryness, especially if a harsh detergent is
used. Therefore, non-soap-based cleansers and mild synthetic
detergents (pH of 5.5–6.0) that protect the skin’s acid mantle are
recommended for patients with AD (105).
While treating flares with TCSs can offer rapid and effective
relief from symptoms, their long-term use carries potential safety
concerns, such as cutaneous adverse events and possible systemic
side effects (119). Over the years, however, these concerns have
escalated into phobias (120), particularly among parents of pediat-
ric AD patients (121–123). These phobias led to treatment non-
compliance (120) and ultimately reduced disease control, which
increased morbidity and the burden of the disease.
‘Corticophobia’ might also explain, at least partially, why patients
often delay treatment of flares, resulting in the disease needlessly
going untreated for extended periods. The introduction of a non-
steroidal treatment option for patients with AD – TCIs (or topical
immunomodulators) – is thus intended to complement the exist-
ing treatment choices and overcome the negatives associated
with TCS therapy (103,124).
TCSs have been the mainstay of AD treatment for over
40 years. When a patient with AD first applies one of the more
potent variants, the benefit is often rapid and apparent. However,
increasing the potency of the preparation in response to tachy-
phylaxis (drug tolerance) (125) may lead to local adverse events.
Furthermore, the side effects of persistent daily applications of a
potent TCS can be unfavorable. As discussed above, prolonged
use of TCSs can potentially damage the skin barrier, resulting in
thinning of the skin, telangiectasia, or striae distensae (60,61,125).
The potency of a TCS is partly determined by the amount of vaso-
constriction produced and the degree to which it inhibits inflam-
mation. Thus, a mild TCS can be used to treat a mild AD flare.
The TCIs, tacrolimus and pimecrolimus, are not recommended as
first-line therapy for AD in England and Wales (103,104). TCIs do
not damage the skin barrier and are therefore particularly useful
on skin sites with a thin skin barrier such as the face and flexures,
which are most vulnerable to the adverse effects of TCSs (126).
TCIs should be used only in the absence of clinical infections. For
the use of both TCSs and TCIs, maintenance treatment twice per
week can be helpful in reducing the frequency and severity of
flares, although TCIs are preferable because of their positive
effects on the skin barrier (103,126). The correct use of all topical
therapies should be demonstrated by specialist dermatology
nurses and care plans should be provided as part of an intensive
educational package (103,104). Phototherapy may also be used in
patients whose medical, physical, and/or psychological states are
greatly affected by their AD (103). Narrowband ultraviolet B (UVB)
light is the most common form of phototherapy because of its
relative efficacy, availability, and provider comfort level. Though
there are few risks associated with narrowband UVB (127), there is
a potential risk of skin cancer from using psoralen and ultraviolet
A (PUVA) (128). The risk of skin cancer from narrowband UVB is
not well established, as a systematic review found no increased
risk compared with PUVA (129) and another review found insuffi-
cient evidence of risk (130). Phototherapy is not appropriate for
young children, and, for all patients, the need to attend treatment
sessions three times per week can impact adversely on school,
work, or other commitments.
Systemic therapy using oral immunosuppressants can only be
used in severe, non-responsive cases of AD. It is essential to
ensure that topical therapies have been used to their maximum
potential by giving comprehensive and repeated education and
demonstration (103,104,131). Oral cyclosporine, azathioprine, and
Table 1. Holistic assessment of atopic dermatitis (AD) and treatment options for children under the age of 12 years (103).
Skin/physical severity Impact on quality of life and psychosocial
well-being
Stepped approach to treatment
Clear Normal skin, no evidence of active eczema No impact on quality of life
Mild Areas of dry skin, infrequent itching (with/
without redness)
Little impact on everyday activities, sleep, and
psychosocial well-being
Emollients, mild potency topical
corticosteroids (TCSs)
Moderate Areas of dry skin, frequent itching, redness
(with/without excoriation and localized
skin thickening)
Moderate impact on everyday activities and
psychosocial well-being, frequently
disturbed sleep
Emollients, moderate potency TCSs, topical
calcineurin inhibitors (TCIs), bandages
and dressings
Severe Widespread areas of dry skin, incessant itching
(with/without excoriation, extensive skin
thickening, bleeding, oozing, cracking,
alteration of pigmentation)
Severe limitation of everyday activities and
psychosocial functioning, nightly loss
of sleep
Emollients, potent TCSs, TCIs, bandages and
dressings, phototherapy, systemic therapy
Adapted from NICE, 2007 (103).
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methotrexate are all effective systemic treatments (132–136).
While the effect of cyclosporine is rapid, azathioprine- and metho-
trexate-induced improvements tend to emerge later.
Immunosuppressant use, however, is associated with significant
side effects and requires careful monitoring (133–136).
Discussion
Despite common worldwide principles and protocols in dermatol-
ogy, significant differences in global treatment methods and
approaches exist. For example, systemic immunosuppressants are
used more frequently in the UK and the USA than in Japan (137).
Furthermore, their use differs across European countries, as
reported by the European Treatment of Severe Atopic Eczema in
Children Taskforce (TREAT) survey (138). Azathioprine, for instance,
is used more often as a first- or second-line systemic treatment
option in the UK than in other European countries, whereas oral
corticosteroids are used less frequently in the UK than in Italy, the
Netherlands, Spain, or Sweden. Such variations in treatment habits
and approaches are not surprising in the pediatric population
given the scarcity of randomized controlled AD trials and the
absence of any licensed therapies.
Several new targeted approaches are emerging, which may
enhance the safe and effective management of patients with AD.
Dupilumab is a fully human monoclonal antibody directed against
the shared IL-4 receptor a subunit that inhibits IL-4 and IL-13,
which are key drivers of type 2/Th2-mediated inflammation.
Dupilumab is approved for subcutaneous administration for the
treatment of patients aged 12 years in the USA with moderate-
to-severe AD inadequately controlled with topical prescription
therapies or when those therapies are not advisable (139), for the
treatment of adult AD patients not adequately controlled with
existing therapies in Japan and for use in patients aged  12
years with moderate-to-severe AD who are candidates for sys-
temic therapy in the European Union (140).
Through a combination of appropriate access to services,
appropriate diagnosis, and appropriate use of existing
approaches, we can make a significant contribution to patient
benefit. However, we are entering an exciting phase of develop-
ment where the number of available treatments for patients is
likely to increase, offering enhanced potential to treat them safely
and effectively, and to address a significant unmet need.
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